Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac<sup>®</sup> in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa
For more than a century, epidemic meningococcal disease mainly caused by serogroup A <i>Neisseria meningitidis</i> has been an important public health problem in sub-Saharan Africa. To address this problem, an affordable meningococcal serogroup A conjugate vaccine, MenAfriVac<sup>®...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/4/617 |